Target intelligence / Profile preview

Peptidyl-prolyl cis-trans isomerase-like 3 (PPIL3)

Target
PPIL3
Molecular classification
Enzyme, Peptidyl-prolyl isomerase, Cyclophilin family
01

Overview

Peptidyl-prolyl cis-trans isomerase-like 3 (PPIL3) is a member of the cyclophilin family of peptidyl-prolyl isomerases, enzymes that catalyze the cis-trans isomerization of proline imide bonds in peptides and proteins[1][3][4]. This protein can function both as a catalyst for protein folding and as a molecular chaperone. PPIL3 directly interacts with the viral protein Apoptin in tumor cells, regulating Apoptin's cytoplasmic localization and, thereby, its apoptosis-inducing function in cancer cells[1]. Like other cyclophilins, PPIL3 may also play roles in pre-mRNA splicing, and its gene is alternatively spliced to produce different isoforms. Cyclophilin J (CYPJ), a synonym for PPIL3, is upregulated in certain cancers and has been proposed as a biomarker and potential therapeutic target[1][2]. The protein binds the immunosuppressant cyclosporine, though the physiological and clinical relevance of this interaction for PPIL3 specifically is not fully established[2].

Other names
Cyclophilin JCyPJCYPJPPIaseRotamase PPIL3Peptidylprolyl cis-trans isomerase-like protein 3Cyclophilin-like protein PPIL3Cyclophilin-like protein 3PPIase-like protein 3
02

Mechanism of action

Inhibition of isomerase activity (cyclosporine and derivatives)

03

Biological functions

Protein foldingCatalysis of cis-trans isomerization of prolyl imide bondsMolecular chaperone activityRegulation of apoptosis (via interaction with Apoptin in tumor cells)
04

Disease associations

Cancer (notably through modulation of Apoptin localization in tumor cells and upregulation/role in certain carcinomas)Potential biomarker/therapeutic target in malignancyOther (regulation of cell cycle progression in related cyclophilins)
05

Safety considerations

No well-documented, target-specific safety concerns; general class effects for cyclophilin inhibition may include immunosuppression (e.g., for cyclosporine)
06

Interacting drugs

cyclosporine (pan-inhibitor of cyclophilins with evidence of binding PPIL3 in biochemical studies)
07

Biomarkers

Upregulation or altered expression in specific cancer types (as inferred from studies on related proteins and some direct evidence)

Beyond the preview

Go deeper on Peptidyl-prolyl cis-trans isomerase-like 3 (PPIL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase-like 3 (PPIL3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call